Yuanjun Guo, Zhengyu Gao, Edward L LaGory, Lewis Wilson Kristin, Jamila Gupte, Yan Gong, Matthew J Rardin, Tongyu Liu, Thong T Nguyen, Jason Long, Yi-Hsiang Hsu, Justin K Murray, Julie Lade, Simon Jackson, Jun Zhang
BACKGROUND: Human genetic studies have identified several mitochondrial amidoxime-reducing component 1 (MTARC1) variants as protective against metabolic dysfunction-associated steatotic liver disease. The MTARC1 variants are associated with decreased plasma lipids and liver enzymes and reduced liver-related mortality. However, the role of mARC1 in fatty liver disease is still unclear. METHODS: Given that mARC1 is mainly expressed in hepatocytes, we developed an N-acetylgalactosamine-conjugated mouse Mtarc1 siRNA, applying it in multiple in vivo models to investigate the role of mARC1 using multiomic techniques...
May 1, 2024: Hepatology Communications